GlaxoSmithKline: the GSK share price is down 12% in a month. Should I sell my shares?

The GlaxoSmithKline share price is down 12% in a month and 35% in a year. Should I give up on GSK by selling my shareholding in this British giant?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

What should investors do when core shareholdings fall out of favour? Should they cut their losses by selling up and moving on? Or should they stick with key stocks by holding on for future recovery? At the moment, this is my dilemma with my largest shareholding, my shares in £62.3bn pharma giant GlaxoSmithKline (LSE: GSK). The GSK share price seems to be in freefall, so is should I give up and invest elsewhere?

GlaxoSmithKline shares head for 10-year lows

The GSK share price hovered around 1,217p, down 1.7% on Friday as I wrote this (although it finished the day ‘only’ 1.08% down). Also, it has fallen 12.1% over the past month. This puts GSK at #100/100 among FTSE 100 shares in terms of share-price performance over the past 30 days. Ouch.

Furthermore, GSK’s share price is down 11.2% over three months, 18.8% over six months, 25.7% over a year, 21.1% over two years, 6.% over three years and 10.2% over five years. Thus, GlaxoSmithKline’s stock has been in steady decline for a long, long time. As a GSK shareholder, I regret not selling in January last year, before Covid-19 wreaked havoc on global markets. On 17 January 2020, GSK shares closed at 1,846p and then peaked at an intraday high of 1,857p a week later. This was the GSK share price’s highest point in almost two decades, approaching levels not seen since 2001. Now, 13 months later, they have crashed more than a third (-34.5%) from their 2020 high.

Three reasons why I’ll keep holding GSK

The fall in the value of my family’s GSK holdings over the past 13 months has been very steep. By my reckoning, it is more than enough to buy a lovely holiday home. Yet, despite this substantial paper loss, we’ll hang onto our GlaxoSmithKline shares for now. Here’s why.

First, as GSK’s share price falls, its dividend yield increases. With the yearly dividend stuck at 80p a share for the past five years, GSK now offers an even higher income stream. At 6.5% a year, it’s more than twice the dividend yield of the wider FTSE 100. As we hold GSK largely for income, I would prefer to keep our share of its £4bn yearly cash payout.

Second, GSK’s most recent quarterly results revealed 2020 sales up 1% to £34bn, pre-tax profit up 16% to £7bn, and earnings per share (EPS) of 115.5p, up 23%. It also confirmed an expected dividend of — you guessed it! — 80p a share for 2021. Though EPS will decline in 2021/22, GlaxoSmithKline aims to launch at least 20 new biopharma products by 2026.

Third, as a long-term value investor, I like buying (and not selling) cheap stocks. And I see GSK shares as very cheap in historical terms. Today, they trade on a price-to-earnings ratio of 10.5 and an earnings yield of 9.5%. Nowadays, hardly any UK large-cap shares offer such generous fundamentals to patient investors.

I’ll keep buying more GSK shares

Of course, my faith in GlaxoSmithKline could be very misplaced. Mr Market doesn’t ring a bell when a share price is set to rebound. The GSK share price could continue to decline. It might even fall below £10 to prices not seen in a quarter-century. But I’m optimistic that next year’s split into two companies (biopharma and consumer healthcare) could be positive for shareholders. Hence, I will continue to reinvest my GSK dividends into buying yet more of this dirt-cheap FTSE 100 share!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Cliffdarcy owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Here’s what a FTSE 100 exit could mean for the Shell share price

As the oil major suggests quitting London for New York, Charlie Carman considers what impact such a move could have…

Read more »

Two white male workmen working on site at an oil rig
Investing Articles

Shell hints at UK exit: will the BP share price take a hit?

I’m checking the pulse of the BP share price after UK markets reeled recently at the mere thought of FTSE…

Read more »

Investing Articles

Why I’m confident Tesco shares can provide a reliable income for investors

This FTSE 100 stalwart generated £2bn of surplus cash last year. Roland Head thinks Tesco shares look like a solid…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

£20,000 in savings? I’d buy 532 shares of this FTSE 100 stock to aim for a £10,100 second income

Stephen Wright thinks an unusually high dividend yield means Unilever shares could be a great opportunity for investors looking to…

Read more »

Investing Articles

Everyone’s talking about AI again! Which FTSE 100 shares can I buy for exposure?

Our writer highlights a number of FTSE 100 stocks that offer different ways of investing in the artificial intelligence revolution.

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

3 top US dividend stocks for value investors to consider in 2024

I’m searching far and wide to find the best dividend stocks that money can buy. Do the Americans have more…

Read more »

Investing Articles

1 FTSE dividend stock I’d put 100% of my money into for passive income!

If I could invest in just one stock to generate a regular passive income stream, I'd choose this FTSE 100…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

Forecasts are down, but I see a bright future for FTSE 100 dividend stocks

Cash forecasts for UK dividend stocks are falling... time to panic! Actually, no. I reckon the future has never looked…

Read more »